These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 1973045)

  • 21. An open study of interferon in HIV-antibody-positive men.
    Ellis ME; Haeney MR; Craske J; Potter MR; Turner AJ; Shipman J; Blackburn N
    AIDS; 1989 Dec; 3(12):851-3. PubMed ID: 2576630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three open-label studies of oral interferon alpha in the treatment of HIV disease.
    Jordan WC
    J Natl Med Assoc; 1994 Apr; 86(4):257-62. PubMed ID: 8040900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low dose oral interferon alpha 2a in HIV-1 seropositive patients: a double-blind, placebo-controlled trial.
    Wright SE; Hutcheson DP; Cummins JM
    Biotherapy; 1998; 11(4):229-34. PubMed ID: 9950098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged asymptomatic states in HIV-seropositive persons with 50 CD4+ T-cells/mm3: preliminary psychoimmunologic findings.
    Solomon GF; Benton D; Harker JO; Bonavida B; Fletcher MA
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1172-3. PubMed ID: 8105075
    [No Abstract]   [Full Text] [Related]  

  • 25. Low-dose oral use of human interferon-alpha in cancer patients.
    Cummins MJ; Pruitt B
    J Interferon Cytokine Res; 1999 Aug; 19(8):937-41. PubMed ID: 10476941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha 2 in natural respiratory viral infections.
    Hayden FG; Gwaltney JM; Johns ME
    Antiviral Res; 1985 Apr; 5(2):111-6. PubMed ID: 4015079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection.
    Lang JM; Touraine JL; Trepo C; Choutet P; Kirstetter M; Falkenrodt A; Herviou L; Livrozet JM; Retornaz G; Touraine F
    Lancet; 1988 Sep; 2(8613):702-6. PubMed ID: 2901566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WHO on low-dose oral interferon-alpha for AIDS.
    Lancet; 1990 Oct; 336(8720):935. PubMed ID: 1976944
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of chronic delta hepatitis with recombinant alpha 2 interferon in 8 patients with anti-human immunodeficiency virus antibodies].
    Taillan B; Fuzibet JG; Pesce A; Vinti H; Gratecos N; Cassuto JP; Dujardin P
    Presse Med; 1988 Nov; 17(41):2200. PubMed ID: 2974582
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of chronic type D hepatitis and concomitant human immunodeficiency infection with alpha-interferon.
    Buti M; Esteban R; Jardi R; Rodriguez-Frias F; Allende H; Cotrina M; Guardia J
    J Hepatol; 1992 Mar; 14(2-3):412-3. PubMed ID: 1500708
    [No Abstract]   [Full Text] [Related]  

  • 31. Low dose oral alpha interferon (LDOAI) study.
    PI Perspect; 1996 Sep; (No 19):16. PubMed ID: 11363900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of alpha 2-interferon against the common cold.
    Foy HM; Fox JP; Cooney MK
    N Engl J Med; 1986 Aug; 315(8):513-4. PubMed ID: 3736634
    [No Abstract]   [Full Text] [Related]  

  • 33. Oromucosal Administration of Interferon to Humans.
    Beilharz MW; Cummins MJ; Bennett AL; Cummins JM
    Pharmaceuticals (Basel); 2010 Jan; 3(2):323-344. PubMed ID: 27713254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pilot study to determine the safety and feasibility of oropharyngeal administration of own mother's colostrum to extremely low-birth-weight infants.
    Rodriguez NA; Meier PP; Groer MW; Zeller JM; Engstrom JL; Fogg L
    Adv Neonatal Care; 2010 Aug; 10(4):206-12. PubMed ID: 20697221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oropharyngeal administration of colostrum to extremely low birth weight infants: theoretical perspectives.
    Rodriguez NA; Meier PP; Groer MW; Zeller JM
    J Perinatol; 2009 Jan; 29(1):1-7. PubMed ID: 18769379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral application of cytokines.
    Georgiades JA; Fleischmann WR
    Biotherapy; 1996; 8(3-4):205-12. PubMed ID: 8813332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study.
    Cummins JM; Mock RE; Shive BW; Krakowka S; Richards AB; Hutcheson DP
    Vet Immunol Immunopathol; 1995 Apr; 45(3-4):355-60. PubMed ID: 7676616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorption of cytokines via oropharyngeal-associated lymphoid tissues. Does an unorthodox route improve the therapeutic index of interferon?
    Bocci V
    Clin Pharmacokinet; 1991 Dec; 21(6):411-7. PubMed ID: 1723667
    [No Abstract]   [Full Text] [Related]  

  • 39. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1).
    Koech DK; Obel AO; Minowada J; Hutchinson VA; Cummins JM
    Mol Biother; 1990 Jun; 2(2):91-5. PubMed ID: 1973045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1).
    Babiuch L; Mian M; Kamińska E; Szymańska B; Georgiades JA
    Arch Immunol Ther Exp (Warsz); 1993; 41(3-4):213-9. PubMed ID: 7907465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.